50424-28-7

Usage

Uses

Used in Pharmaceutical Research:
6-Methoxy-quinazolin-4-ylamine is used as a precursor or building block for the synthesis of biologically active compounds, leveraging its unique structure and properties to contribute to the development of novel pharmaceutical agents.
Used in Medicinal Chemistry:
6-METHOXY-QUINAZOLIN-4-YLAMINE is utilized in medicinal chemistry for its potential biological activities, which may include interactions with specific biological targets or pathways, thereby offering insights into its mechanisms of action and therapeutic potential.
Used in Drug Development:
6-Methoxy-quinazolin-4-ylamine is employed in drug development to explore its potential as a pharmacological agent, with the aim of identifying and optimizing its therapeutic applications in various disease areas.
Used in Biological Systems Research:
6-METHOXY-QUINAZOLIN-4-YLAMINE is used in research to investigate its specific interactions and mechanisms of action within biological systems, providing valuable information for the advancement of drug discovery and therapeutic strategies.
Overall, 6-Methoxy-quinazolin-4-ylamine's applications span across various stages of pharmaceutical research and development, from the synthesis of biologically active compounds to the investigation of its pharmacological properties and therapeutic potential. Its versatility and potential impact on drug discovery make it a valuable asset in the pursuit of novel therapeutic agents.

InChI:InChI=1/C9H9N3O/c1-13-6-2-3-8-7(4-6)9(10)12-5-11-8/h2-5H,1H3,(H2,10,11,12)

Upstream product

• 19181-64-7 6-Methoxyquinazolin-4-one 
• 179246-11-8 4-chloroquinazoline-6-yl acetate 
• 16064-10-1 6-hydroxyquinazolin-4(3H)-one 
• 179688-15-4 3,4-dihydro-4-oxoquinazolin-6-yl acetate 
• 848438-50-6 4-chloroquinazolin-6-ol 
• 74-88-4 methyl iodide 
• 1882-69-5 5-methoxy-2-nitro-benzoic acid 
• 394-31-0 2-amino-5-hydroxybenzoic acid 
• 77287-34-4 formamide 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 1882-72-0 methyl 2-amino-5-hydroxybenzoate 
• 2475-80-1 methyl 2-amino-5-methoxybenzoate 
• 19181-64-7 6-methoxyquinazolin-4-ol 

Downstream Products

• 150450-42-3 4-{[3',4'-(methylenedioxy)benzyl]amino}-6-methoxyquinazoline 
• 2327-45-9 methyl 2-nitro-5-(methoxy)benzoate 
• 169205-79-2 N-(3-bromophenyl)-6-methoxyquinazolin-4-amine 
• 683269-72-9 4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexanol 

Relevant academic research and scientific papers

Quinazoline and phthalazine derivatives as novel melatonin receptor ligands analogues of agomelatine

For further development of successors of Agomelatine through modulation of its pharmacokinetic properties, we report herein the design, synthesis and pharmacological results of a new family of melatonin receptor ligands. Issued from the introduction of quinazoline and phthalazine scaffolds carrying an ethyl amide lateral chain and a methoxy group as bioisosteric ligands analogues of previously developed Agomelatine. The biological activity of the prepared analogues was compared with that of Agomelatine. Quinazoline and phthalazine rings proved to be a versatile scaffold for easy feasible MT1 and MT2 ligands. Potent agonists with sub-micromolar binding affinity were obtained. However, the presence of two nitrogen atoms resulted in compounds with lower affinity for both MT1 and MT2, in comparison with the parent compound, balanced by the exhibition of good pharmacokinetic properties.

Intramolecular Ring-Opening of Oxetanes: Access to Functionalised Hydroxymethyl 2,3-Dihydroimidazo[1,2- c ]quinazolines

An intramolecular oxetane ring-opening was developed, affording novel 2-(hydroxymethyl)-2,3-dihydroimidazo[1,2- c ]quinazolines from N -(3-methyloxetan-3-yl)quinazolin-4-amines under mild conditions. The resulting medicinally relevant tricyclic scaffolds were synthesised in good yields with diverse substituents. Moreover, reaction optimisation led to the development of a one-pot procedure.

CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS

Provided are cyclic iminopyridimdine compounds and their bicyclic derivatives, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to B-Raf V600E kinase.

IDENTIFICATION AND USE OF ERK5 INHIBITORS

The present invention covers heterocyclic compounds of general formula (I) in which T, U, Y, Z, R1 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer disorders, as a sole agent or in combination with other active ingredients.

Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1

The ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) was recently shown to promote mineralization of the aortic valve, hence, its inhibition represents a significant target. A quinazoline-4-piperidine sulfamide compound (QPS1) has been described as a specific and non-competitive inhibitor of NPP1. We report herein the synthesis and in vitro inhibition studies of novel quinazoline-4-piperidine sulfamide analogues using QPS1 as the lead compound. Of the 26 derivatives prepared, four compounds were found to have Ki 105 nM against human NPP1.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists

A series of TRPA1 antagonists is described having a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine or a 1-aryloxyisoquinoline scaffold. These compounds have high ligand efficiency and favorable physical properties and may thus serve as scaffolds for further optimization.

4-Aminoquinazoline Derivatives and Uses Thereof

The present invention provides a 4-aminoquinazoline derivative having the chemical structure of the following formula, and the use thereof. It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present

Switching the Chemoselectivity in the Amination of 4-Chloroquinazolines with Aminopyrazoles

[Chemical equation presented] The chemoselectivity in the amination of 4-chloroquinazolines with 3-amino-1H-pyrazoles was studied. Under the conditions of Pd2(dba)3/ Xantphos/Na2CO3, 4-chloroquinazolines underwent selective amination with the cyclic secondary amino group of 3-amino-1H-pyrazoles. whereas 4-chloroquinazolines were exclusively aminated with the primary amino group of 3-amino-1H-pyrazoles via SNAr substitution In the presence of HCl.

NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES

The present invention relates to a bifunctional compound of formula I or its pharmaceutically acceptable salts or solvates A-L-B (I) wherein A is a histone deacetylase (HDAC) inhibitory moiety, L is a single bond or a linker group and B is a protein kinase inhibitory moiety. The bifunctional compound according to formula (I) is useful for the treatment of malignant and non-malignant neoplasia and diseases related to abnormal cell growth